ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2020 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Borderline ovarian tumors in pregnancy
About authors
1 Family Planning and Reproduction Center, Moscow, Russia
2 Pirogov Russian National Research Medical University, Moscow, Russia
Correspondence should be addressed: Pyotr A. Klimenko
Sevastopolsky prospect, 24а, Moscow, 117209; ur.liam@oknemilk.ap
About paper
Compliance with ethical standards: the study was approved by the Ethics Committee of Pirogov Russian National Research Medical University (protocol № 176 dates June 25, 2018). The informed consent was submitted by all study participants.
Author contribution: all authors contributed to the research and manuscript preparation equally, read the approved the final version of the article before publishing.
Received: 2020-04-07
Accepted: 2020-04-21
Published online: 2020-04-27
|
Fig. 1. Ovarian tumors/tumor-like formations distribution in accordance with the histological structure, stage (BOTs/ malignant ovarian tumors) and abnormality degree
(ovarian cancer)
Fig. 2. Morphology of BOTs and malignant ovarian tumors in pregnant women. А. Borderline serous ovarian cystadenoma (×10, hematoxylin and eosin staining). B. Poorly differentiated serous ovarian carcinoma (×10, hematoxylin and eosin staining). C. Borderline mucinous ovarian cystadenoma (×10, hematoxylin and eosin staining). D. Mucinous ovarian carcinoma (×10, hematoxylin and eosin staining).
Fig. 3. CD31 expression in the malignant ovarian tumor (×20). Vessels are
marked with arrows
Fig. 4. CD31 expression in the borderline ovarian tumor (×20). Vessels are marked with arrows
